BC Extra | Oct 16, 2019
Company News

Shionogi antibiotic overcomes mortality concerns to win FDA panel’s support

Shionogi & Co. Ltd. (Tokyo:4507) said FDA’s Antimicrobial Drugs Advisory Committee on Wednesday recommended approving Fetroja cefiderocol to treat complicated urinary tract infections including pyelonephritis caused by Gram-negative bacteria in patients with limited or no...
BC Extra | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

China’s Joint Procurement Office announced steep price cuts for companies that won the tender bids for 25 drugs in the nationwide expansion of its pilot program for centralized procurement of generic and off-patent originator drugs....
BC Week In Review | Apr 26, 2019
Company News

Lilly divests China rights to legacy antibiotics to Eddingpharm

Lilly sold Chinese rights to Vancocin vancomycin and Ceclor cefaclor, as well as a Ceclor manufacturing plant in Suzhou, to Eddingpharm for $375 million in a deal slated to close late 2019 or early 2020....
BC Innovations | Apr 2, 2019
Distillery Therapeutics

Two phenothiazines to treat meningitis

DISEASE CATEGORY: Infectious disease INDICATION: Meningitis Cell culture and mouse studies identified two phenothiazine-based compounds that could help treat meningitis caused by Neisseria meningitides . In cultures of primary human endothelial cells isolated from dermal microvessels...
BC Week In Review | Sep 28, 2018
Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop and commercialize VNRX-5133 in combination with cefepime. The deal covers Greater China, South Korea and Southeast Asia...
BC Extra | Sep 25, 2018
Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop and commercialize VNRX-5133 in combination with cefepime. The deal covers Greater China, South Korea and Southeast Asia...
BC Week In Review | Sep 14, 2018
Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

Merck & Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III ASPECT-NP trial to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Zerbaxa was non-inferior to meropenem in...
BC Week In Review | Apr 27, 2018
Clinical News

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) reported preclinical data from a mouse model of cephalosporin-resistant Klebsiella pneumoniae lung infection showing that VNRX-5133 plus the cephalosporin antibiotic cefepime led to greater reductions in mean bacterial lung titers...
BC Week In Review | Oct 27, 2017
Financial News

China Resources planning China pharma fund

The China Resources Pharmaceutical Equity Investment Fund Management (Shantou) Company Ltd. subsidiary of drug distribution company China Resources Pharmaceutical Group Ltd. (HKSE:3320) proposed to raise RMB2,500 million ($376.8 million) in its China Resources Pharmaceutical Industrial...
BC Week In Review | Oct 27, 2017
Company News

NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...
Items per page:
1 - 10 of 288